Revelation Biosciences Stock: Retail Interest Soars After Positive Trial Results

Revelation Biosciences Inc. (REVB), a nano-cap biopharmaceutical company, has captured the attention of retail investors in a big way.

On Wednesday, REVB saw the highest jump in new retail watchers on Stocktwits, with its following increasing by a staggering 8.79%, as shares doubled in value and became one of the top gainers on U.S. stock exchanges.  

The surge in interest stems from Revelation's recent success in a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy.

The trial confirmed the safety and effectiveness of escalating doses of Gemini, while also showcasing significant, dose-dependent changes in biomarkers indicative of the drug's ability to stimulate the immune system.  

Encouraged by these results, Revelation CEO James Rolke announced plans to rapidly move forward with a Phase 1b study involving patients later in 2024.

Gemini is being developed as a single-dose pre-treatment for two specific purposes: to prevent or reduce the severity of acute kidney injury (AKI) in patients undergoing cardiac surgery; and reduce the incidence, duration, and severity of post-surgical infections.

The positive clinical trial data and the upcoming Phase 1b study have fueled an ‘extremely bullish’ sentiment (89/100) on Stocktwits, with message volume soaring by a remarkable 4,427% over the past 24 hours on Wednesday.

While REVB was among the top gainers in the previous session, it tumbled by 31% on Thursday after the company announced exercising warrants to purchase additional shares at a reduced price.

Share

·

Add us on